2016
DOI: 10.1097/scs.0000000000002250
|View full text |Cite
|
Sign up to set email alerts
|

The Efficacy and Safety of Tranexamic Acid in Cranio-Maxillofacial and Plastic Surgery

Abstract: The antifibrinolytic drug tranexamic acid (TXA) is effective in reducing blood loss and transfusion requirements in other fields of elective surgery and its use is emerging in a number of plastic surgical subspecialties. This systematic review and meta-analysis evaluates the current evidence for the efficacy and safety of TXA in craniomaxillofacial, head and neck, breast, aesthetic, burns, and reconstructive microsurgery. We searched PubMed, EMBASE, Medline, The Cochrane Database of Systematic Reviews and the … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
49
0
1

Year Published

2016
2016
2021
2021

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 65 publications
(50 citation statements)
references
References 45 publications
(52 reference statements)
0
49
0
1
Order By: Relevance
“…Considering all surgical procedures, tranexamic acid has been shown to reduce blood loss by approximately one‐third. It has been shown specifically to reduce blood loss, and the rate of allogeneic blood transfusions after coronary artery surgery, spinal surgery, orthopaedic fracture surgery, prostate surgery, caesarean section or hysterectomy and plastic surgery procedures.…”
Section: Surgical Strategiesmentioning
confidence: 99%
“…Considering all surgical procedures, tranexamic acid has been shown to reduce blood loss by approximately one‐third. It has been shown specifically to reduce blood loss, and the rate of allogeneic blood transfusions after coronary artery surgery, spinal surgery, orthopaedic fracture surgery, prostate surgery, caesarean section or hysterectomy and plastic surgery procedures.…”
Section: Surgical Strategiesmentioning
confidence: 99%
“…Minimally invasive techniques are attractive, particularly in young infants (< 6 months), as alternatives involve a long bicoronal scar, prolonged hospitalization, substantial blood loss and with a high chance of requiring allogenic transfusion requirements. (2)(3)(4)(5) The first SAC was reported by Lauritzen et al (6) The principle of SAC is to use the viscoelastic properties of the immature skull to widen the vault and reduce cranial length.…”
Section: Introductionmentioning
confidence: 99%
“…Similarly, use of TA in lowering blood loss and need for transfusion has been documented in various published studies pertaining to Obstetrics/Gynecology, Orthopedics, Head and Neck and Cardiac surgery (27,28,29,30).…”
Section: Discussionmentioning
confidence: 92%